Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Strong Buy

Exponential Moving Average

Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Travere Therapeutics, Inc. Common Stock (TVTX)

Pharmaceutical Preparations

https://www.travere.com

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

3611 VALLEY CENTRE DR, SUITE 300
SAN DIEGO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/23/2003

Market Cap

665,476,050

Shares Outstanding

75,150,000

Weighted SO

75,145,831

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

DICE --.--%

CYTK --.--%

VTYX --.--%

COGT --.--%

NUVL --.--%

CERE --.--%

GPCR --.--%

RVMD --.--%

AKRO --.--%

Beta

0.7750

Last Div

0.0000

Range

5.12-15.39

Chg

-0.0800

Avg Vol

1133780

Mkt Cap

665476050

Exch

NASDAQ

Country

US

Phone

888 969 7879

DCF Diff

N/A

DCF

0.0000

Div Yield

0.0000

P/S

3.7461

EV Multiple

-3.0504

P/FV

44.5139

Div Yield %

0.0000

P/E

-4.6211

PEG

-0.0704

Payout

0.0000

Current Ratio

3.0427

Quick Ratio

2.9934

Cash Ratio

0.2663

DSO

56.0227

DIO

68.9938

Op Cycle

125.0165

DPO

298.3614

CCC

-173.3449

Gross Margin

0.8220

Op Margin

-2.1299

Pretax Margin

-2.1565

Net Margin

-0.8214

Eff Tax Rate

-0.0009

ROA

-0.2647

ROE

-1.0243

ROCE

-0.8802

NI/EBT

0.3809

EBT/EBIT

1.0125

EBIT/Rev

-2.1299

Debt Ratio

0.6955

D/E

25.3045

LT Debt/Cap

0.9615

Total Debt/Cap

0.9620

Int Coverage

-31530.6667

CF/Debt

-0.7536

Equity Multi

36.3848

Rec Turnover

6.5152

Pay Turnover

1.2233

Inv Turnover

5.2903

FA Turnover

7.7079

Asset Turnover

0.3223

OCF/Share

-3.7271

FCF/Share

-4.1084

Cash/Share

4.1986

OCF/Sales

-1.6260

FCF/OCF

1.1023

CF Coverage

-0.7536

ST Coverage

-55.9471

CapEx Coverage

-9.7758

Div&CapEx Cov

-9.7758

P/BV

44.5139

P/B

44.5139

P/S

3.7461

P/E

-4.6211

P/FCF

-2.0900

P/OCF

-2.3342

P/CF

-2.3342

PEG

-0.0704

P/S

3.7461

EV Multiple

-3.0504

P/FV

44.5139

DPS

0.0000

Latest Headlines (EST)

Benzinga Nov 08, 02:05 Travere Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire Inc. Nov 08, 02:05 Travere Therapeutics Announces Pricing of Public Offering of Common Stock Benzinga Jan 18, 15:00 Cracking The Code: Understanding Analyst Reviews For Travere Therapeutics GlobeNewswire Inc. Jan 02, 16:30 Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference Benzinga Dec 15, 15:01 Where Travere Therapeutics Stands With Analysts GlobeNewswire Inc. Dec 14, 07:30 Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU) GlobeNewswire Inc. Nov 21, 16:30 Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference Zacks Investment Research Nov 07, 18:30 Travere (TVTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Zacks Investment Research Nov 07, 18:30 Travere (TVTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Zacks Investment Research Nov 07, 18:30 Travere (TVTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Zacks Investment Research Nov 07, 18:30 Travere (TVTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates GlobeNewswire Inc. Nov 03, 10:46 Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023 GlobeNewswire Inc. Nov 03, 10:46 Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023

Revenue Product Segmentation